Sobi and ADC Therapeutics Ink Licensing Deal Worth Up to $435 Million

Sobi has inked a licensing agreement with ADC Therapeutics for the company’s cancer drug, Zynlonta (loncastuximab tesirine-lpyl), for treatment of all hematologic and solid tumor indications outside of the United States, greater China, Singapore and Japan.

Under the terms of the agreement, ADC Therapeutics will receive an upfront payment of $55 million and is eligible to receive $50 million if the drug gains EU approval for third-line treatment of diffuse large B-cell lymphoma (DLBCL). The company is also eligible for approximately $330 million for reaching additional regulatory and sales milestones.

The EU has granted Zynlonta orphan drug designation for the treatment of DLBCL and accepted its marketing authorization application in October 2021.

Zynlonta was granted FDA accelerated approval in April 2021 as a single-agent intravenous treatment for adult patients with relapsed or refractory DLBCL after two or more lines of systemic therapy.